Document is current
Any future updates will be listed below
-
Authors
Vecchié, Alessandra https://orcid.org/0000-0003-0410-5996
Del Buono, Marco Giuseppe https://orcid.org/0000-0002-7483-6164
Chiabrando, Guido Juan
Dentali, Francesco
Abbate, Antonio https://orcid.org/0000-0002-1930-785X
Bonaventura, Aldo https://orcid.org/0000-0002-4747-5535
- License Information
-
More Information
Article History
Accepted: 7 July 2021
First Online: 1 October 2021
Compliance with Ethical Standards
:
: Dr. Bonaventura received a travel grant from Kiniksa Pharmaceuticals Ltd. and honoraria from Effetti s.r.l. (Milan, Italy).Dr. Vecchié received a travel grant from Kiniksa Pharmaceuticals Ltd. and honoraria from Effetti s.r.l. (Milan, Italy).Dr. Abbate has served as a consultant for Applied Clinical Intel, AstraZeneca, Cromos Pharma, Effetti s.r.l, Janssen, Kiniksa Pharmaceuticals Ltd., Eli Lilly, Merck, Olatec, Swedish Orphan Biovitrum, Novo Nordisk, and Serpin Pharma. He has also has received research support from Janssen, Olatec, Novartis, R-Pharm, and Serpin Pharma. In addition, Dr. Abbate has a patent Novel cryopyrin inhibitor issued, and a patent Alpha-1 antitripsin to treat cardiovascular conditions pending.All other authors declare no competing interests.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
